Clinical trial · Interventional
Laser Ablation of Papillary Thyroid Microcarcinoma
Pilot Study to Evaluate the Safety and Efficacy of Percutaneous Laser Ablation of Thyroid Papillary Microcarcinoma
NCT04623801CI-TRIAL-00121328active not recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to explore whether percutaneous laser ablation (PLA) is a safe and effective alternative to removing papillary thyroid microcarcinoma (PTMC) with surgery.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Papillary Thyroid Microcarcinoma | Thyroid Gland Papillary Microcarcinoma | ALIAS | 0.90 |
| Thyroid | — | UNRESOLVED | — |
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Percutaneous Laser Ablation (PLA) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Participants with papillary microcarcinoma (PTMC)
- description
- Participants with papillary microcarcinoma (PTMC) who have elected to proceed with thyroidectomy rather than an observational management approach will be considered as potential candidates for this trial.
- interventionNames
- Procedure: Percutaneous Laser Ablation (PLA)
Primary outcomes (1)
- measure
- Number of participants with complete thermal ablation
- timeFrame
- 6 months
- description
- Complete thermal ablation of the targeted PTMC (T1aN0M0) as determined by histological examination of thyroid tissue obtained by either thyroid lobectomy or total thyroidectomy 6 months after PLA.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years * Papillary thyroid cancer documented by * (a) Bethesda VI cytology, * (b) Bethesda III, IV, V, or VI cytology AND BRAF V600E mutation, or * (c) Bethesda V cytology AND high risk ultrasonographic features documented by either the ATA high suspicion or TIRADS 5 nodule characteristics To ensure the majority of cases will be eligible based on criteria (a) or (b), we will enroll ≤ 2 patients based on criteria (c). * Maximum diameter ≤ 13 mm * Declined active surveillance * The thyroid lesion must be primarily solid with ≤ 25% cystic compent * No US evidence of extrathyroidal extension through the thyroid capsule * No imaging evidence of lymph node metastasis * Preserved contralateral vocal cord function prior to PLA Exclusion Criteria: * Thyroid cancer that is non papillary thyroid cancer (PTC) * Thyroid lesion with \> 25% cystic component * Lesion with US evidence of extrathyroidal extension through the thyroid capsule * Clinical or ultrasonographic evidence of lymph node metastasis * Pregnancy
References
Publications (0)
Data not yet available
No reference posted for this study.